Date Title Description PDF
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download
21 Feb 2023 On business and financial situation The company releases the Integrated Report for the year 2022 Download
21 Feb 2023 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
23 Nov 2022 On business and financial situation The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day   Download
04 Nov 2022 On business and financial situation The Company releases the press release related to the first nine months of 2022 financial results Download

Pages

Date Title Description PDF
28 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 Download
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download

Pages

Date Title Description PDF
27 Feb 2014 Informe anual de remuneraciones de consejeros 2013 Download
27 Nov 2013 Acuerdos estratégicos con terceros Download
26 Nov 2013 Acuerdos estratégicos con terceros Download
07 Nov 2013 Información sobre resultados (4) Download
07 Nov 2013 Información sobre resultados (3) Download

Pages